CRA was hired by a biotech company with a new product in development for oncology. The main objective was to quantitatively understand current treatment dynamics and future market opportunity. We evaluated multiple data sources and developed patient flow and market map for two tumor types, using a patient-level claim data. We further created competitive landscape assessment and identified target intervention points for each scenario, in collaboration with the client. Research was conducted for both US and EU5 to size the global commercial opportunity.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...